Skip to Content
  • MyChart

    Log in to our secure, personalized website to manage your care (formerly myMDAnderson).

  • Request an Appointment

    If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start.

    Appointment Information
    New Patients Current Patients Referring Physicians
  • Every Breakthrough
    Begins With You

    Gifts to UT MD Anderson’s historic philanthropic campaign help accelerate discovery, transform lives and bring hope to more patients than ever before.

    Learn more about Only Possible Here
    Donate Today only-possible-here-logo
The University of Texas MD Anderson Cancer Center
  • Clinical Trials
  • Locations
  • Careers
  • Contact Us
  • Our Doctors
    • Español
    • عربى
    • 中文
    • Türkçe
Clear
close
      MyChart
      Donate Today
      • Clinical Trials
      • Locations
      • Careers
      • Contact Us
        • Español
        • عربى
        • 中文
        • Türkçe
      • Request an Appointment
      • New Patients
      • Current Patients
      • Referring Physicians
      • Patients & Family
          • Becoming Our Patient Home
          • Why UT MD Anderson
          • Planning for Care
          • Getting to UT MD Anderson
          • While You're Here
          • International Center
          • Services and Amenities
          • Insurance & Billing
          • Second Opinion Appointments
          • Diagnosis & Treatment Home
          • Cancer Types
          • A New Diagnosis
          • Treatment Options
          • Care Centers & Clinics
          • Emotional & Physical Effects
          • Patient Support
          • Clinical Trials
          • Supporting a Loved One Home
          • Caregiver Roles & Challenges
          • Children and Teens
          • Taking Care of Yourself
          • Helping a UT MD Anderson Patient
          • Dealing with Loss
          • Life After Cancer Home
          • Follow-up Care After Cancer Treatment
          • Long-Term Effects of Cancer
          • Social & Emotional Impacts of Cancer
          • Legal & Financial Impacts of Cancer
          • Survivorship Week
        • Request an Appointment Current Patients

          Find information and resources for current and returning patients.

          Clinical Trials

          Learn about clinical trials at UT MD Anderson and search our database for open studies.

      • Prevention & Screening
          • Manage Your Risk Home
          • Tobacco Control
          • Diet
          • Body Weight
          • Physical Activity
          • Skin Safety
          • HPV
          • Hepatitis
          • Alcohol
          • Family History Home
          • Genetic Testing
          • Hereditary Cancer Syndromes
          • Genetic Counseling and Testing FAQs
          • Cancer Screenings Home
          • Mammograms & Breast Cancer Screening
          • Cervical Cancer Screening
          • Colorectal Cancer Screening
          • Endometrial Cancer Screening
          • Liver Cancer Screening
          • Lung Cancer Screening
          • Mobile Mammography
          • Ovarian Cancer Screening
          • Prostate Cancer Screening
          • Skin Cancer Screening
          • Women's Cancer Screening
          • Men's Cancer Screening
        • Cancer Prevention Center 

          The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.

      • Donors & Volunteers
          • Donate Home
          • Raise Money
          • Honor Loved Ones
          • Create Your Legacy
          • Endowments
          • Caring Fund
          • Matching Gifts
          • Foundation and Corporation Relations
          • Volunteer Home
          • Why Volunteer
          • On-Site Volunteers
          • Volunteer Endowment
          • Patient Experience
          • Teen Volunteer Leadership Program
          • Children's Cancer Hospital Councils
          • Other Ways to Help Home
          • Give Blood
          • Shop UT MD Anderson
          • Children's Art Project
          • Donate Goods or Services
          • Attend Events
          • Cord Blood Bank
          • Corporate Alliances Home
          • Current Alliances
        • Join the Campaign to End Cancer 

          Help us celebrate and fuel the groundbreaking innovations and transformative advancements that define UT MD Anderson.

      • For Physicians
          • Refer a Patient Home
          • Health Care Provider Resource Center
          • Referring Provider Team
          • Insurance Information
          • International Referrals
          • myMDAnderson for Physicians
          • Second Opinion Pathology
          • Clinical Trials Home
          • Clinical Tools & Resources Home
          • Clinical Calculators
          • Clinical Practice Algorithms
        • myMDAnderson for Physicians 

          Our personalized portal helps you refer your patients and communicate with their UT MD Anderson care team.

      • Research
          • Departments, Labs and Institutes Home
          • Departments and Divisions
          • Labs
          • Research Centers and Programs
          • Institutes
          • Specialized Programs of Research Excellence (SPORE) Grants
          • Research Areas Home
          • Basic Science
          • Translational Research
          • Clinical Research
          • Prevention & Personalized Risk Assessment
          • Research Resources Home
          • Excellence in Science
          • Core Facilities and Services
          • Conferences & Seminars
          • Why Research at UT MD Anderson
          • STRIDE
          • NCI-Designated Cancer Center
          • Data Resources
        • Clinical Trials 

          As part of our mission to eliminate cancer, UT MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers.

      • Education & Training
          • Degree-Granting Schools Home
          • School of Health Professions
          • MD Anderson UTHealth Houston Graduate School
          • Research Training Home
          • Early Career Pathway Programs
          • Predoctoral Training
          • Postdoctoral Training
          • Mentored Faculty Programs
          • Career Development
          • Clinical Training Home
          • Graduate Medical Education
          • Clinical Education for Non-Physicians
          • Nursing Education & Training
          • Continuing Education & Review Courses
          • Simulation Center
          • Continuing Education & Professional Development Home
          • Continuing Professional Education/Conferences
          • Administrative Internships & Fellowships
          • Cancer Survivorship Professional Education
          • Leadership Institute
          • Patient Home Visits
          • Education Resources Home
          • Alumni Relations
          • Education Design Services
          • Awards & Recognitions
          • Academic Mentoring Council
          • Why UT MD Anderson & Houston
          • Outreach Programs Home
          • Project ECHO
          • Observer Programs
          • Comparative Effectiveness Training (CERTaIN)
          • Faculty Speakers Bureau
        • Apply to SHP

          Choose from 12 allied health programs at School of Health Professions.

          Research Trainees

          View open postdoctoral and other research trainee positions.

          GME Fellowships

          Learn about our graduate medical education residency and fellowship opportunities.

      Matthew S. Ning Image

      Matthew S. Ning, MD, MPH

      Department of Thoracic Radiation Oncology, Division of Radiation Oncology

      Present Title & Affiliation

      Primary Appointment

      Associate Professor, Thoracic Radiation Oncology, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

      Patient Experience Officer, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

      Education Director (Department level), Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

      Director of Clinical Value, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

      Dual/Joint/Adjunct Appointment

      Associate Professor, Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

      Education & Training

      Degree-Granting Education

      2019The University of Texas Health Science Center, Houston, Texas, US, MPH in Healthcare Management
      2015Vanderbilt University School of Medicine, Nashville, Tennessee, US, Doctorate of Medicine, MD
      2011Virginia Polytechnic Institute and State University, Blacksburg, Virginia, US, BS in Biochemistry

      Postgraduate Training

      2025-2026Health Policy Fellowship, American Society for Radiation Oncology (ASTRO)
      2016-2020Clinical Residency, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
      2015-2016Clinical Internship, Internal Medicine, MedStar Washington Hospital Center, Washington, DC

      Licenses & Certifications

      2021American Board of Radiology (ABR)
      2020Texas Medical Board
      2020Drug Enforcement Agency (DEA)

      Experience & Service

      Faculty Academic Appointments

      Assistant Professor, Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2026

      Administrative Appointments/Responsibilities

      Patient Experience Officer, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - Present

      Resident Education Director, Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - Present

      Director of Clinical Value, Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present

      Other Professional Positions

      Cancer Network: Thoracic Site Director and Faculty Lead, Radiation Oncology, University of Texas MD Anderson Cancer Center, 2025 - Present

      Intramural Institutional Committee Activities

      Invited Member, Thoracic Radiation Oncology Chair Advisory Committee, The University of Texas MD Anderson Cancer Center, 2025 - 2026

      Chair, Radiation Oncology Finance Committee, The University of Texas MD Anderson Cancer Center, 2025 - Present

      Chair, Rad Onc Patient Experience Committee (ROPEC), UT MD Anderson Cancer Center, 2025 - Present

      Member, Thoracic Rad Onc Patient Education Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present

      Moderator, Esophageal Multidisciplinary Tumor Board Conference, The University of Texas MD Anderson Cancer Center, 2024 - Present

      Clinical Co-Lead, PTC2/Proton Disease Site Transition & Development: Thoracic Working Group, The University of Texas MD Anderson Cancer Center, 2023 - Present

      Elected Representative (Senator), Institutional Faculty Senate, The University of Texas MD Anderson Cancer Center, 2022 - 2025

      Member, Rad Onc Residency: Clinical Competency Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present

      Lead, Rad Onc Insurance Workflow Automation Working Group, The University of Texas MD Anderson Cancer Center, 2022 - Present

      Member, Radiation Oncology Finance Committee, The University of Texas MD Anderson Cancer Center, 2022 - 2025

      Elected Representative, PRS Clinical Revenue Cycle Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2025

      Member, Radiation Oncology: New Technology Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present

      Rad Onc Back-Up AMD, Thoracic Center Multidisciplinary Leadership Team, The University of Texas MD Anderson Cancer Center, 2020 - 2021

      Lead, Radiation Oncology Clin Ops: Billing & Reimbursement Working Group, The University of Texas MD Anderson Cancer Center, 2020 - Present

      Co-Lead, Radiation Oncology Operational Tier System Working Group, The University of Texas MD Anderson Cancer Center, 2020 - 2021

      Member, Radiation Oncology Cancer Network Research Steering Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present

      Data Analyst, Radiation Oncology COVID-19 Tracer Team, The University of Texas MD Anderson Cancer Center, 2020 - 2020

      Member, Radiation Oncology Alternative Payment Model (APM) Working Group, The University of Texas MD Anderson Cancer Center, 2020 - 2021

      Clinical Co-Lead, Proton Therapy Center Health Economics Committee, The University of Texas MD Anderson Cancer Center, 2019 - Present

      Member, Radiation Oncology Quality & Safety Committee, The University of Texas MD Anderson Cancer Center, 2017 - 2020

      Extramural Institutional Committee Activities

      Invited Member, ASTRO Code Development and Valuation Subcommittee, American Society for Radiation Oncology (ASTRO), 2025 - Present

      Invited Member, ASTRO Health Policy Committee, American Society for Radiation Oncology (ASTRO), 2025 - Present

      Vice-Chair, ASTRO Code Utilization and Application Committee, American Society for Radiation Oncology (ASTRO), 2025 - Present

      Consultant, American Radium Society (ARS) Appropriate Use Criteria (AUC): Thoracic Committee, American Radium Society (ARS), 2025 - 2026

      Nominated Clinical Member (Rad Onc Representative), Novitas Solutions Jurisdiction H (JH) Contractor Advisory Committee (CAC), Novitas Solutions, 2024 - Present

      Selected Member, ASTRO Payor Relations Committee, American Society for Radiation Oncology (ASTRO), 2023 - Present

      Selected Member, ASTRO Code Utilization and Application Committee, American Society for Radiation Oncology (ASTRO), 2023 - 2025

      Voting Member, American Radium Society (ARS) Appropriate Use Criteria (AUC): Thoracic Committee, American Radium Society (ARS), 2023 - 2025

      Honors & Awards

      2026Awesome Job Award (for Caring), The University of Texas MD Anderson Cancer Center
      2026Excellence in Education Award (Radiation Oncology), The University of Texas MD Anderson Cancer Center
      2025Awesome Job Award (for Core Value: Caring), UT MD Anderson Cancer Center
      2025ROC-STaR Award: for Clinical and Administrative Coverage (during Staffing Shortage), UT MDACC
      2024Luis Delclos Excellence in Teaching Award, MDACC Rad Onc Residency Class of 2024
      2024Awesome Job Award x2 (for Patient Education and Clinical Stewardship), UT MDACC
      2024ROC-STaR Award (x2): for Patient Education and Clinical Coverage (during Emergency Weather), UT MDACC
      2024Top 10% Care Provider: Patient Experience & Satisfaction, CG-CAHPS (Press Ganey)
      2023Awesome Job Award (for Administrative Leadership), UT MDACC
      2022Top 1% Care Provider: Patient Experience & Satisfaction, CG-CAHPS (Press Ganey)
      2021ROC-STaR Award: Radiation Oncology Commendations and Recognition, UT MDACC
      2020Awesome Job Award (for Excellent Patient Care), UT MDACC
      2020James D. Cox Award for Research Excellence, Gilbert H. Fletcher Society
      2020ROC-STaR Award (x2): Radiation Oncology Commendations and Recognition, UT MDACC
      2020Diagnostic Imaging Celebrate Solutions: Clinical Quality Project Winner (2nd Place), UT MDACC
      2019Bristol-Myers Squibb Population Science Competition Finalist, UT MDACC
      2019ASRT Invited Faculty Travel Grant, American Society of Radiologic Technologists
      2019Delta Omega Honorary Society, UT Health
      2019Lean Bronze Certification, UT MDACC Quality College
      2019Thomas H. & Mayme P. Scott Cancer Research Fellowship, UT MDACC
      2018RSNA Research Resident Grant, Radiological Society of North America
      2018ABS Prostate and GYN School Scholarship, American Brachytherapy Society
      2018Lean Six Sigma Yellow Belt Certification, UT Health
      2017Best of ASTRO, American Society for Radiation Oncology
      2013ASA Student Grant Targeting Melanoma and Skin Cancer, American Skin Association
      2012Meharry/VICC/TSU Cancer Partnership Grant, Meharry/VICC/TSU Cancer Partnership
      2012VICTR Translational Pilot Funding, Vanderbilt Institute for Clinical and Translational Research
      2011 - 2015VMS Williams Tuition Scholarship, Vanderbilt University School of Medicine
      2011Phi Beta Kappa Academic Society, Virginia Tech
      2011Outstanding Graduating Senior of the College of Science, Virginia Tech

      Selected Presentations & Talks

      Local Presentations

      1. 2024. Radiation for Rapid Cytoreduction (non-BRAF). Invited. Anaplastic Thyroid Cancer Research Retreat. Houston, Texas, US.
      2. 2024. Insurance Automation Workflows in Radiation Oncology. Invited. Procedures and Therapeutics Division Semi-Annual Operational Retreat. Houston, Texas, US.
      3. 2023. Tumor Board. Panelist. Thyroid Cancer Management in the Era of Precision Medicine: Experiential Training Program for Bayer. Houston, Texas, US.
      4. 2019. Enhancing the Value of Radiation Therapy: Novel Indications, Better Outcomes, and Lower Costs (Grand Rounds). Invited. Houston, Texas, US.
      5. 2019. The Insurance Approval Process for Proton Radiation Therapy: A Significant Barrier to Patient Care with Coverage Gaps for Vulnerable Populations (Oral Presentation Competition in Population Science Research). Conference. Bristol-Myers Squibb. Houston, Texas, US.
      6. 2019. Operations Management in Radiation Oncology: Standardizing Radiation Treatment Scheduling Timelines Using a Data-Driven Tier System (Seminar Lecture). Invited. Houston, Texas, US.

      National Presentations

      1. 2025. Navigating the Independent Review Organization (IRO) Process for Insurance Appeals. Invited. NAPT Insurance and Appeals Roundtable, US.
      2. 2025. Independent Review Organization (IRO) Insurance Appeals Process: Multistate Analysis and Legal Procedural Strategies. Panelist. National Association for Proton Therapy (NAPT) Annual Meeting. Philadelphia, Pennsylvania, US.
      3. 2025. Delivery of Care: The Evolution of Radiotherapy Technology: Implications for Treatment Delivery and Reimbursement. Invited. American Cancer Executives (ACE) 2025. New Orleans, Louisiana, US.
      4. 2024. MD Anderson Meet the Faculty Experts: Thoracic. Panelist. American Society for Radiation Oncology (ASTRO) 2024. Washington, D.C, District of Columbia, US.
      5. 2024. Challenging Lung/Thoracic Cases: Central/Ultracentral SBRT and Salvage Reirradiation. Invited. American Society for Radiation Oncology (ASTRO) 2024. Washington, D.C, District of Columbia, US.
      6. 2024. Cost-Effectiveness of Proton Beam Therapy for H&N Cancer. Invited. National Association for Proton Therapy (NAPT) 2024 Annual Meeting. Boston, Massachusetts, US.
      7. 2023. Financial and Profitability Analysis of Clinical Trial Patients. Invited. MD Anderson Cancer Network Meeting (at ASTRO 2023). San Diego, California, US.
      8. 2023. Proton Therapy for Thoracic Malignancies: Novel Indications and Trends. Invited. Banner Health Thoracic Multidisciplinary Operations Meeting, US.
      9. 2022. Challenging NSCLC Cases: Central, Ultracentral, and Reirradiation. Invited. American Society for Radiation Oncology (ASTRO) 2022 Conference. San Antonio, Texas, US.
      10. 2021. Independent Review Organization (IRO) Insurance Appeal Analysis. Invited. Insurance Authorization Webinar, US.
      11. 2021. Proton Therapy Training Seminar: Liver and Thoracic Sites. Invited, US.
      12. 2021. LA-NSCLC: Definitive, Adjuvant, and Salvage Radiation Therapy. Invited. LA-NSCLC: Definitive, Adjuvant, and Salvage Radiation Therapy, CA, US.
      13. 2020. Proton Therapy for Thoracic Malignancies: Non-Small Cell Lung Cancer. Invited, OK, US.
      14. 2020. Improving Patient Access to Proton Therapy through Stakeholder Collaboration: Three-Year Outcomes of a Prospective Statewide Insurance Coverage Pilot with a Self-Funded Employer Plan (Webinar). Invited. Washington, DC, US.
      15. 2019. Predictors of Mid-Treatment Mortality for Patients Undergoing Palliative Radiation Therapy: Improving the Quality of End-of-Life Care. Conference. Predictors of Mid-Treatment Mortality for Patients Undergoing Palliative Radiation Therapy: Improving the Quality of End-of-Life Care. Chicago, IL, US.
      16. 2019. Operations Management in Radiation Oncology: Standardizing Radiation Treatment Scheduling Timelines Using a Data-Driven Tier System. Conference. Operations Management in Radiation Oncology: Standardizing Radiation Treatment Scheduling Timelines Using a Data-Driven Tier System. Chicago, IL, US.
      17. 2018. Cervical Contouring and Inoperable Endometrial Cases. Conference. Cervical Contouring and Inoperable Endometrial Cases. Houston, TX, US.
      18. 2018. Quantifying institutional resource utilization of adjuvant brachy and IMRT for endometrial cancer via time-driven activity-based costing. Conference. Quantifying institutional resource utilization of adjuvant brachy and IMRT for endometrial cancer via time-driven activity-based costing. San Francisco, CA, US.
      19. 2017. Outcomes and Patterns of Relapse after Definitive Radiation Therapy for Oligometastatic Cervical Cancer. Conference. Outcomes and Patterns of Relapse after Definitive Radiation Therapy for Oligometastatic Cervical Cancer. San Diego, CA, US.

      International Presentations

      1. 2024. Phase I Trial of Adjuvant Pembrolizumab after Radiotherapy for Lung-Intact Malignant Pleural Mesothelioma. Invited. Merck Investigator Studies Program (MISP) Scientific Input Engagement (SIE) at ESMO. Barcelona, ES.
      2. 2024. MD Anderson Meet the Faculty Experts: Radiation Oncology. Panelist. European Society for Medical Oncology (ESMO). Barcelona, ES.
      Read More
      Less

      Grant & Contract Support

      Date: 2026 - Present
      Title:Proton Beam Therapy Health Economics Evidence Generation
      Funding Source:Ion Beam Applications (Belgium)
      Role:PI
      Date: 2022 - 2024
      Title:Establishing the value of proton therapy for head and neck cancer: Assessing cost-effectiveness, comparative effectiveness, and financial toxicity of therapy
      Funding Source:National Assocation for Proton Therapy (NAPT) Health Economics Research Initiative (HERI)
      Role:Co-I
      ID:FP00015187

      Selected Publications

      Peer-Reviewed Articles

      1. Cabanillas ME, Busaidy NL, Zafereo M, Iyer PC, Wang JR, Hamidi S, Ferrarotto R, Liu S, Gunn GB, Spiotto M, Lee A, Maniakas A, Gule-Monroe M, Williams MD, Hosseini SM, Banuchi VE, Hu MI, Ning M, Dadu R. Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial. Eur J Cancer 246:117013, 2026. e-Pub 2026. PMID: 42673705.
      2. Lin R, Chen M, Zhang X, Xu T, Xu T, Maguire RC, Corrigan KL, Koutroumpakis E, Chang JY, Lin SH, Chen AB, Nguyen QN, Gandhi SJ, Ning MS, Bronk J, Chun S, Ajdari A, Niedzielski JS, Yang J, Chen X, Pan T, Meng QH, Tsao AS, Deswal A, Mohan R, Liao Z. Bayesian Learning to Reduce Cardiac Risk of Patients With Locally Advanced Non-Small Cell Lung Cancer Based on Personalized Radiation Therapy Prescription. Int J Radiat Oncol Biol Phys 125(3):949-958, 2026. e-Pub 2026. PMID: 41365476.
      3. Xu X, Saad MB, Grippin A, Xu H, Muneer A, Young E, Lin SH, Liao Z, Gandhi S, Balter P, Ning MS, Qian D, Bronk JK, Chen A, O'Reilly M, Nguyen QN, Welsh J, Pollard-Larkin JM, Heymach JV, Lee JJ, Wu J, Chang JY. Brief Report: SARS-CoV-2 mRNA Vaccination Improved Survival in NSCLC Treated with Radiotherapy. J Thorac Oncol:103956, 2026. e-Pub 2026. PMID: 42229634.
      4. Thaker NG, Liu W, Waddle M, Showalter T, Mastroleo F, Luh J, Levitt C, Ning M, Loaiza-Bonilla A, Hong J. Retrieval-Augmented Generation in Oncology: Promises, Pitfalls, and Early Applications. AI Precis Oncol 3(2-3):34-45, 2026. e-Pub 2026. PMID: 42305950.
      5. Hamidi, S, Vodopivec, DM, Busaidy, NL, Gule-Monroe, MK, Akhave, NS, Banuchi, VE, Ferrarotto, R, Fournier, I, Gunn, GB, Iyer, PC, Lee, A, Maniakas, A, Marczyk, VR, Ning, M, Sousa, LG, Spiotto, MT, Waguespack, SG, Wang, RJ, Zafereo, M, Cabanillas, ME, Dadu, R. Real-World Experience with Lenvatinib plus Pembrolizumab in Metastatic BRAF Wild-Type Anaplastic Thyroid Carcinoma. Thyroid : official journal of the American Thyroid Association 36(2):153-161, 2026. e-Pub 2026. PMID: 41791883.
      6. Frank, SJ, Busse, PM, Lee, JJ, Rosenthal, D, Hernandez, M, Swanson, DM, Garden, AS, Gunn, GB, Patel, SH, Snider, JW, Ma, DJ, Molitoris, JK, Lee, N, Parvathaneni, U, McDonald, MW, Kalman, NS, Lin, A, Mohammed, N, Henson, CE, Hyde, C, Bajaj, GK, Katz, SR, Dagan, R, Morrison, WH, Reddy, JP, Fuller, C, Shah, SJ, Phan, J, Chronowski, G, Mayo, LL, Sturgis, EM, Ferrarotto, R, Zhu, XR, Zhang, X, Wang, L, Hutcheson, KA, El-Naggar, AK, Moreno, AC, Lee, A, Spiotto, MT, Gross, N, Lai, SY, Liao, JJ, Paly, JJ, Liao, Z, Foote, RL, Bates, JE, Chambers, MS, Chun, SG, Kaiser, A, Lester, SC, Lukens, JN, McGee, LA, Neben-Wittich, MA, Nguyen, Q, Routman, DM, Schlembach, PJ, Skinner, H, Soike, MH, Rwigema, JM, Wiederhold, LR, Blanchard, P, Choi, I, Koong, A, Langendijk, H, Mohan, R, Carlson, BJ, Mapps, A, Sarmiento, JG, Teferra, MY, Bosch, WR, Followill, DS, Taylor, PA, Fuentes, SY, Ning, M, Toumazis, I, Wogan, CF, De Gracia, B, Fink, K, Grippin, A, Ma, J, Pettersen, EA, Sareyeldin, RM, Cronin, C, Muise, S, Johnson, M, Pyfferoen, K, Tranby, BN, Leonard, J, Watkin, S, Eggleston, C, Barrow, B, Wolcott, J, Antonio, J, Brand, J, Cleverdon, A, Drake, M, Peters, E, Small, C, Clark, K, Holder, R. Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA. The Lancet 407(10524):174-184, 2026. e-Pub 2026. PMID: 41391462.
      7. Sims, TT, Court, K, El Alam, MB, Ramatlho, P, Ketlametswe, R, Ning, M, Robertson, ES, Schmeler, KM, Colbert, LE, Klopp, AH, Grover, S. Cervical and Tumor-Associated Microbiomes in Botswana Women With and Without HIV With Carcinoma of the Cervix Before and After Definitive Chemoradiation. JCO Global Oncology 11, 2025. e-Pub 2025. PMID: 41160784.
      8. Rajan SS, Ning MS, Jacobson M, Simiele SJ, Bruno T, Kouzy R, Yoshida-Court K, Cisneros-Napravnik T, Yu H, Stafford J, Kim Y, Mathew G, Cordova RA, Domingo M, Jhingran A, Lin LL, Joyner M, Sims TT, Colbert L, Venkatesan AM, Klopp A. Iterative intraoperative 3T MRI (iMRI)-guided brachytherapy: A prospective study on enhancing implantation precision and dosimetric gains in advanced gynecologic cancers. Brachytherapy 24(6):844-853, 2025. e-Pub 2025. PMID: 40816920.
      9. Odwuor A, Lee P, Chang JY, Gandhi S, Liao Z, Lin SH, Chen A, Nguyen QN, O'Reilly MS, Chun SG, Bronk J, Qian D, Ning MS. Outcomes and Toxicity following 3 or More Definitive Courses of Thoracic Radiation Therapy for Non-Small Cell Lung Cancer. Clin Lung Cancer 26(5):384-392, 2025. e-Pub 2025. PMID: 40318943.
      10. Cabanillas, ME, Akhave, NS, Banuchi, VE, Busaidy, NL, Dadu, R, Ferrarotto, R, Gunn, GB, Hamidi, S, Hofmann, M, Hosseini, SM, Iyer, PC, Lai, SY, Lee, A, Maniakas, A, Ning, M, Spiotto, MT, Wang, RJ, Williams, MD, Zafereo, M. Reimagining the Therapeutic Approach for Anaplastic Thyroid Cancer. Thyroid 35(5):462-470, 2025. e-Pub 2025. PMID: 40388579.
      11. Brooks ED, Sio TT, Ning MS, Morris CG, Mendenhall NP, Turner M, Vergara NK, Palmer M, Artz ME. Independent Review Organization and Proton Therapy: Multistate Analysis and Legal Procedural Strategies. Int J Part Ther 15:100741, 2025. e-Pub 2025. PMID: 40084161.
      12. Salazar, RM, Nair, SS, Leone, A, Xu, T, Mumme, R, Duryea, J, De, BS, Corrigan, KL, Rooney, MK, Ning, M, Das, P, Holliday, EB, Liao, Z, Court, LE, Niedzielski, JS. Performance Comparison of 10 State-of-the-Art Machine Learning Algorithms for Outcome Prediction Modeling of Radiation-Induced Toxicity. Advances in Radiation Oncology 10(2), 2025. e-Pub 2025. PMID: 39717195.
      13. Hamidi S, Ning MS, Phan J, Zafereo ME, Gule-Monroe MK, Dadu R. Recurrent Poorly Differentiated Thyroid Cancer Successfully Treated With Radiation and Immunotherapy. JCEM Case Rep 3(2):luaf015, 2025. e-Pub 2025. PMID: 39866918.
      14. Cabanillas, ME, Dadu, R, Ferrarotto, R, Gule-Monroe, MK, Liu, S, Fellman, B, Williams, MD, Zafereo, M, Wang, RJ, Lu, C, Ning, M, McKinley, BA, Woodman, SE, Duose, D, Gunn, GB, Busaidy, NL. Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma. JAMA Oncology 10(12):1672-1680, 2024. e-Pub 2024. PMID: 39446377.
      15. Dudzinski SO, Cabanillas ME, Hamidi S, Marczyk VR, Busaidy NL, Dadu R, Welsh J, Hu MI, Gunn GB, Wang C, Waguespack SG, Phan J, Beckham TH, Chang JY, Sherman SI, Reddy JP, Ying AK, O'Reilly MS, Chen A, Lee A, Gandhi SJ, Liao Z, Ludmir EB, Nguyen QN, Lin SH, Zafereo ME, Ning MS. Definitive Radiotherapy for Oligometastatic and Oligoprogressive Thyroid Cancer: A Potential Strategy for Systemic Therapy Deferral. J Natl Compr Canc Netw 23(1), 2024. e-Pub 2024. PMID: 39662038.
      16. Park, HS, Rimner, A, Amini, A, Chang, JY, Chun, SG, Donington, J, Edelman, MJ, Gubens, M, Higgins, K, Iyengar, P, Juloori, A, Movsas, B, Nemeth, Z, Ning, M, Rodrigues, GB, Wolf, A, Simone, C. Appropriate Use Criteria (AUC) for the Management of Non-Small Cell Lung Cancer in a Central/Ultra-Central Location. Journal of Thoracic Oncology 19(12):1640-1653, 2024. e-Pub 2024. PMID: 39271016.
      17. Amini, A, Zaha, VG, Hamad, E, Woodard, PK, Rimner, A, Chang, JY, Chun, SG, Donington, J, Edelman, MJ, Gubens, M, Higgins, K, Iyengar, P, Juloori, A, Movsas, B, Ning, M, Park, HS, Rodrigues, GB, Wolf, A, Simone, C. American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy. Journal of Thoracic Oncology 19(12):1654-1667, 2024. e-Pub 2024. PMID: 39313150.
      18. Ning, M, Odwuor, A, Chang, JY, Gandhi, S, Liao, Z, Lin, SH, Chen, A, Welsh, J, Nguyen, Q, O'Reilly, M, Chun, SG, Bronk, JK, Qian, DC, Lee, PP. Salvage Reirradiation with Proton Beam Therapy for Locoregionally Recurrent Non-Small Cell Lung Cancer. Cancers 16(21), 2024. e-Pub 2024. PMID: 39518028.
      19. Wang, L, Ding, Y, Bruno, TL, Stafford, RJ, Lin, E, Bathala, TK, Sanders, JW, Ning, M, Ma, J, Klopp, AH, Venkatesan, AM, Wang, J, Martirosyan, KS, Frank, SJ. A Novel Positive-Contrast Magnetic Resonance Imaging Line Marker for High-Dose-Rate (HDR) MRI-Assisted Radiosurgery (MARS). Cancers 16(10), 2024. e-Pub 2024. PMID: 38792000.
      20. Rodrigues G, Higgins KA, Rimner A, Amini A, Chang JY, Chun SG, Donington J, Edelman MJ, Gubens MA, Iyengar P, Movsas B, Ning MS, Park HS, Wolf A, Simone CB 2nd. American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non-Small Cell Lung Cancer. JAMA Oncol, 2024. e-Pub 2024. PMID: 38602670.
      21. Corrigan KL, Xu T, Sasaki Y, Lin R, Chen AB, Welsh JW, Lin SH, Chang JY, Ning MS, Gandhi S, O'Reilly MS, Gay CM, Altan M, Lu C, Cascone T, Koutroumpakis E, Sheshadri A, Zhang X, Liao L, Zhu XR, Heymach JV, Nguyen QN, Liao Z. Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma. Radiother Oncol 193:110121, 2024. e-Pub 2024. PMID: 38311031.
      22. Weng J, Mesko S, Chronowski G, Lee P, Choi S, Das P, Koong AC, French K, Aloia T, Ehlers R, Elrod-Joplin D, Kerr A, Smith R, Martinez W, Bloom E, Shah SJ, Ning MS, Liao Z, Herman J, Moningi S, Moreno AC, Nguyen QN. Optimizing Outpatient Radiation Oncology Consult Workflow by Using Time-Driven Activity-Based Costing: Efficiency and Financial Impacts. JCO Oncol Pract:OP2300037, 2024. e-Pub 2024. PMID: 38330252.
      23. Ludmir EB, Hoffman KE, Jhingran A, Kouzy R, Ip MP, Sturdevant L, Ning MS, Minsky BD, McAleer MF, Chronowski GM, Arzu IY, Reed VK, Garg AK, Roberts T, Eastwick GA, Olson MR, Selek U, Gabel M, Koong AC, Kupferman ME, Kuban DA. Implementation and Efficacy of a Large-Scale Radiation Oncology Case-Based Peer-Review Quality Program across a Multinational Cancer Network. Pract Radiat Oncol 14(3):e173-e179, 2024. e-Pub 2024. PMID: 38176466.
      24. Li H, Hu X, Ning MS, Fuller GN, Stewart JM, Gilliam JC, Wu J, Le X, Vaporciyan AA, Lee JJ, Gibbons DL, Heymach JV, Futreal A, Zhang J. Case report: Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features. Front Oncol 14:1324057, 2024. e-Pub 2024. PMID: 38590653.
      25. Brooks, ED, Giap, F, Cassidy, V, Ning, M, Robbert, B, Redding, P, Palmer, MB, Turner, L, Mendenhall, WM, Klein, S, Mendenhall, N. Strategic Operational Redesign Improves Prior Authorization Access. International Journal of Particle Therapy 10(2):65-72, 2023. e-Pub 2023. PMID: 38075483.
      26. Grover S, Lichter KE, Likhacheva A, Jang JW, Ning MS, Robin TP, Small W, Kudchadker RJ, Swamidas J, Chopra S, Rai B, Sharma SD, Sharma DN, Kuppusamy T, Yang R, Berger D, Mendez LC, Glaser S, Erickson DL, Chino J, Mourtada F, Abdel-Wahab M, Jhingran A, Simonds H, Mahantshetty U. The American Brachytherapy Society and Indian Brachytherapy Society consensus statement for the establishment of high-dose-rate brachytherapy programs for gynecological malignancies in low- and middle-income countries. Brachytherapy 22(6):716-727, 2023. e-Pub 2023. PMID: 37704540.
      27. Jacobsen MC, Rigaud B, Simiele SJ, Rauch GM, Ning MS, Vedam S, Klopp AH, Stafford RJ, Brock KK, Venkatesan AM. Feasibility of quantitative diffusion-weighted imaging during intra-procedural MRI-guided brachytherapy of locally advanced cervical and vaginal cancers. Brachytherapy 22(6):736-745, 2023. e-Pub 2023. PMID: 37612174.
      28. Chun SG, Rimner A, Amini A, Chang JY, Donington J, Edelman MJ, Geng Y, Gubens MA, Higgins KA, Iyengar P, Movsas B, Ning MS, Park HS, Rodrigues G, Wolf A, Simone CB. American Radium Society Appropriate Use Criteria for Radiation Therapy in the Multidisciplinary Management of Thymic Carcinoma. JAMA Oncol 9(7):971-980, 2023. e-Pub 2023. PMID: 37186595.
      29. Li B, Hirata E, Trejo JM, Garcia B, Chang B, Malhotra S, Ning M, Sarria GJ. Exploring the Cost of Radiation Therapy Delivery for Locally Advanced Cervical Cancer in a Public and a Private Center in Latin America Using Time-Driven Activity-Based Costing. Int J Radiat Oncol Biol Phys 115(5):1205-1216, 2023. e-Pub 2023. PMID: 36922083.
      30. De B, Farooqi AS, Mitchell KG, Ludmir EB, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee JJ, Swisher SG, Gibbons DL, Zhang J, Le X, Elamin YY, Gomez DR, Ning MS, Lin SH, Liao Z, Chang JY, Vaporciyan AA, Heymach JV, Antonoff MB, Gandhi SJ. Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival. JCO Precis Oncol 7:e2200540, 2023. e-Pub 2023. PMID: 36716413.
      31. Liu Y, Zhang Z, Rinsurongkawong W, Gay CM, Le X, Ning MS, Lewis J, Rinsurongkawong V, Lee JJ, Roth J, Swisher S, Gandhi S, Lee PP, Gibbons DL, Vaporciyan AA, Heymach JV, Zhang J, Lin SH. Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. JAMA Netw Open 5(6):e2215589, 2022. e-Pub 2022. PMID: 35666500.
      32. McGinnis GJ, Ning MS, Beadle BM, Joubert N, Shaw W, Trauernich C, Simonds H, Grover S, Cardenas CE, Court LE, Smith GL. Barriers and Facilitators of Implementing Automated Radiotherapy Planning: A Multisite Survey of Low- and Middle-Income Country Radiation Oncology Providers. JCO Glob Oncol 8:e2100431, 2022. e-Pub 2022. PMID: 35537104.
      33. Gjyshi O, Lin SH, Pezzi TA, Ning MS, Ma J, Liu S, Rusthoven CG. Care Patterns for Stereotactic Radiosurgery in Small Cell Lung Cancer Brain Metastases. Clin Lung Cancer 23(2):185-190, 2022. e-Pub 2022. PMID: 34419375.
      34. De Leo AN, Dagan R, Amdur RJ, Yeung AR, Li J, Brooks ED, Gilbo P, Gomez D, Chang JY, Ning M. How Three Academic Centers Prescribe SBRT for Primary Lung Cancer. Pract Radiat Oncol 12(6):496-503, 2022. e-Pub 2022. PMID: 35219881.
      35. Brooks ED, Wang X, De B, Verma V, Williamson TD, Hunter R, Mohamed ASR, Ning MS, Zhang X, Chang JY. An algorithm for thoracic re-irradiation using biologically effective dose: a common language on how to treat in a "no-treat zone". Radiat Oncol 17(1):4, 2022. e-Pub 2022. PMID: 34991637.
      36. Boyce-Fappiano D, Ning MS, Gjyshi O, Mesko S, Pasalic D, Chang AJ, Orio PF, Thaker NG. Payment Methodology for the Radiation Oncology Alternative Payment Model: Implications for Practices and Suggestions for Improvement. JCO Oncol Pract 17(12):OP2100200, 2021. e-Pub 2021. PMID: 34097458.
      37. Ning MS, Boyce-Fappiano D, Thaker NG. Oligometastatic Disease in Context of the Radiation Oncology Alternative Payment Model: Implications for Local Consolidative Therapy. JCO Oncol Pract 17(12):OP2100549, 2021. e-Pub 2021. PMID: 34767465.
      38. Chang, JY, Mehran, RJ, Feng, L, Verma, V, Liao, Z, Welsh, J, Lin, SH, O'Reilly, M, Jeter, M, Balter, PA, McRae, SE, Berry, D, Heymach, JV, Roth, JA, Antonoff, MB, Hofstetter, WL, Rajaram, R, Rice, DC, Sepesi, B, Swisher, SG, Vaporciyan, AA, Walsh, GL, DeGraaf, C, Correa, AM, Chen, A, Gandhi, S, Komaki, R, Lee, PP, Nguyen, Q, Ning, M, Gao, S, Pollard-Larkin, JM, Nitsch, PL, Sadagopan, R, Wang, X. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS). The lancet oncology 22(10):1448-1457, 2021. e-Pub 2021. PMID: 34529930.
      39. Grover S, Ning MS, Bale M, Lichter KE, Shah S, Bvochora-Nsingo M, Chiyapo S, Balang D, McGinnis GJ, Ralefala T, Moloi T, Luckett R, Ramogola-Masire D, Robertson ES, Zetola NM. Chemoradiation versus radiation alone in stage IIIB cervical cancer patients with or without human immunodeficiency virus. Int J Gynecol Cancer 31(9):1220-1227, 2021. e-Pub 2021. PMID: 34312220.
      40. Patel RR, He K, Barsoumian HB, Chang JY, Tang C, Verma V, Comeaux N, Chun SG, Gandhi S, Truong MT, Erasmus JJ, Hong DS, Lee PP, Ning MS, Nguyen QN, Heymach JV, Altan M, Blumenschein G, Fossella FV, Sezen D, Chen D, Carter BW, Davies MA, Glitza IC, Diab A, Ferrarotto R, Cabanillas ME, Yuan Y, Shah SJ, Parra ER, Sun B, Cortez MA, Welsh JW. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol 162:60-67, 2021. e-Pub 2021. PMID: 34237343.
      41. Sapienza LG, Ning MS, Carvalho EF, Spratt D, Calsavara VF, McLaughlin PW, Gomes MJL, Baiocchi G, Abu-Isa E. Efficacy and Incontinence Rates After Urethroplasty for Radiation-Induced Urethral Stenosis: A Systematic Review and Meta-Analysis. Urology 152:109-116, 2021. e-Pub 2021. PMID: 33631205.
      42. McGinnis GJ, Ning MS, Bvochora-Nsingo M, Chiyapo S, Balang D, Ralefala T, Lin A, Zetola NM, Grover S. Management of Head and Neck Cancers With or Without Comorbid HIV Infection in Botswana. Laryngoscope 131(5):E1558-E1566, 2021. e-Pub 2021. PMID: 33098322.
      43. Chapman BV, Ning MS, Farnia B, Mesko S, Lin SH, Tang C, Allen PK, Liao Z, Chang JY, Komaki R, Mehran RJ, Gandhi SJ, Gomez DR. Postoperative Radiotherapy for Locally Advanced NSCLC: Implications for Shifting to Conformal, High-Risk Fields. Clin Lung Cancer 22(3):225-233.e7, 2021. e-Pub 2021. PMID: 32727706.
      44. Yeboa DN, Akinfenwa CA, Nguyen J, Amaya D, de Gracia B, Ning M, Cox V, De B, Smith BD, Lin L, Beddar S, Hoang H, Koong A, Liao Z. Effectively Conducting Oncology Clinical Trials During the COVID-19 Pandemic. Adv Radiat Oncol 6(3):100676, 2021. e-Pub 2021. PMID: 33686374.
      45. Ning MS, Das P, Rosenthal DI, Dabaja BS, Liao Z, Chang JY, Gomez DR, Klopp AH, Gunn GB, Allen PK, Nitsch PL, Natter RB, Briere TM, Herman JM, Wells R, Koong AC, McAleer MF. Early and Midtreatment Mortality in Palliative Radiotherapy: Emphasizing Patient Selection in High-Quality End-of-Life Care. J Natl Compr Canc Netw 19(7):1-9, 2021. e-Pub 2021. PMID: 33878727.
      46. Bishop AJ, Livingston JA, Ning MS, Valdez ID, Wages CA, McAleer MF, Paulino AC, Grosshans DR, Woodhouse KD, Tao R, Roth ME, Gunn GB, McGovern SL. Young Adult Populations Face yet another Barrier to Care with Insurers: Limited Access to Proton Therapy. Int J Radiat Oncol Biol Phys 110(5):1496-1504, 2021. e-Pub 2021. PMID: 33677051.
      47. Smith GL, Fu S, Ning MS, Nguyen DK, Busse PM, Foote RL, Garden AS, Gunn GB, Fuller CD, Morrison WH, Chronowski GM, Shah SJ, Mayo LL, Phan J, Reddy JP, Snider JW, Patel SH, Katz SR, Lin A, Mohammed N, Dagan R, Lee NY, Rosenthal DI, Frank SJ. Work Outcomes after Intensity-Modulated Proton Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for Oropharyngeal Cancer. Int J Part Ther 8(1):319-327, 2021. e-Pub 2021. PMID: 34285958.
      48. Thaker NG, Boyce-Fappiano D, Ning MS, Pasalic D, Guzman A, Smith G, Holliday EB, Incalcaterra J, Garden AS, Shaitelman SF, Gunn GB, Fuller CD, Blanchard P, Feeley TW, Kaplan RS, Frank SJ. Activity-Based Costing of Intensity-Modulated Proton versus Photon Therapy for Oropharyngeal Cancer. Int J Part Ther 8(1):374-382, 2021. e-Pub 2021. PMID: 34285963.
      49. Huang D, Frank SJ, Verma V, Thaker NG, Brooks ED, Palmer MB, Harrison RF, Deshmukh AA, Ning MS. Cost-Effectiveness Models of Proton Therapy for Head and Neck: Evaluating Quality and Methods to Date. Int J Part Ther 8(1):339-353, 2021. e-Pub 2021. PMID: 34285960.
      50. Maroongroge S, Smith B, Bloom ES, Ning MS, Wang C, Das P, Koong AC, McAleer MF, Woodhouse KD. Telemedicine for Radiation Oncology in a Post-COVID World. Int J Radiat Oncol Biol Phys 108(2):407-410, 2020. e-Pub 2020. PMID: 32890522.
      51. Pezzi TA, Ning MS, Thaker NG, Boyce-Fappiano D, Gjyshi O, Olivieri ND, Guzman AB, Incalcaterra JR, Mesko S, Gandhi S, Chun S, Tang C, Frank SJ, Gomez DR. Evaluating single-institution resource costs of consolidative radiotherapy for oligometastatic non-small cell lung cancer using time-driven activity-based costing. Clin Transl Radiat Oncol 23:80-84, 2020. e-Pub 2020. PMID: 32529054.
      52. Noticewala SS, Koong AC, Bloom ES, Choi S, Chronowski G, Ghafar RA, Guadagnolo BA, Gunn GB, Klopp A, Lee P, Li J, Liao Z, Ludmir EB, McAleer MF, Nguyen QN, Ning MS, Robinson IJ, Rosenthal DI, Shah SJ, Woodward WA, Zaebst DJ, Dabaja BS, Das P. Radiation Oncology Strategies to Flatten the Curve During the Coronavirus Disease 2019 (COVID-19) Pandemic: Experience From a Large Tertiary Cancer Center. Adv Radiat Oncol 5(4):567-572, 2020. e-Pub 2020. PMID: 32775771.
      53. Sims TT, Biegert GWG, Ramogola-Masire D, Ngoni K, Solley T, Ning MS, El Alam MB, Mezzari M, Petrosino J, Zetola NM, Schmeler KM, Colbert LE, Klopp AH, Grover S. Tumor microbial diversity and compositional differences among women in Botswana with high-grade cervical dysplasia and cervical cancer. Int J Gynecol Cancer, 2020. e-Pub 2020. PMID: 32675252.
      54. Ning MS, Venkatesan AM, Stafford RJ, Bui TP, Carlson R, Bailard NS, Vedam S, Davis R, Olivieri ND, Guzman AB, Incalcaterra JR, McKelvey FA, Thaker NG, Rauch GM, Tang C, Frank SJ, Joyner MM, Lin LL, Jhingran A, Eifel PJ, Klopp AH. Developing an intraoperative 3T MRI-guided brachytherapy program within a diagnostic imaging suite: Methods, process workflow, and value-based analysis. Brachytherapy 19(4):427-437, 2020. e-Pub 2020. PMID: 31786169.
      55. Brooks ED, Ning MS, Palmer MB, Gunn GB, Frank SJ, Shah AK. Strategic Operational Redesign for Successfully Navigating Prior Authorization Barriers at a Large-Volume Proton Therapy Center. JCO Oncol Pract:JOP1900533, 2020. e-Pub 2020. PMID: 32639929.
      56. Ayoub Z, Ning MS, Brooks ED, Kang J, Welsh JW, Chen A, Gandhi S, Heymach JV, Vaporciyan AA, Chang JY. Definitive Management of Presumed Synchronous Early Stage Non-Small Cell Lung Cancers: Outcomes and Utility of Stereotactic Ablative Radiation Therapy. Int J Radiat Oncol Biol Phys 107(2):261-269, 2020. e-Pub 2020. PMID: 32044413.
      57. McGinnis GJ, Ning MS, Nitsch PL, O'Reilly MS, McAleer MF, Koong AC, Chang JY. Rapid Detection of Asymptomatic Coronavirus Disease 2019 by Computed Tomography Image Guidance for Stereotactic Ablative Radiotherapy. J Thorac Oncol 15(6):1085-1087, 2020. e-Pub 2020. PMID: 32311499.
      58. Ning MS, McAleer MF, Jeter MD, Minsky BD, Ghafar RA, Robinson IJ, Nitsch PL, Zaebst DJ, Todd SE, Nguyen J, Lin SH, Liao Z, Lee P, Gunn GB, Klopp AH, Dabaja BS, Nguyen QN, Chronowski GM, Bloom ES, Koong AC, Das P. Mitigating the impact of COVID-19 on oncology: Clinical and operational lessons from a prospective radiation oncology cohort tested for COVID-19. Radiother Oncol 148:252-257, 2020. e-Pub 2020. PMID: 32474129.
      59. Ning MS, Vedam S, Ma J, Stafford RJ, Bruno TL, Cunningham M, Starks C, Lawyer A, Venkatesan AM, Wang L, Wang J, Olivieri ND, Guzman AB, Incalcaterra JR, Thaker NG, Joyner MM, Lin LL, Jhingran A, Eifel PJ, Klopp AH. Clinical utility and value contribution of an MRI-positive line marker for image-guided brachytherapy in gynecologic malignancies. Brachytherapy 19(3):305-315, 2020. e-Pub 2020. PMID: 32265119.
      60. Samson P, Ning MS, Shaverdian N, Shepherd AF, Gomez DR, McGinnis GJ, Nitsch PL, Chmura S, O'Reilly MS, Lee P, Chang JY, Robinson C, Lin SH. Clinical and Radiographic Presentations of COVID-19 among Patients Receiving Radiation Therapy for Thoracic Malignancies. Adv Radiat Oncol, 2020. e-Pub 2020. PMID: 32395673.
      61. Sapienza LG, Ning MS, de la Pena R, McNew LK, Jhingran A, Georgeon L, Rasool N, Gomes MJL, Abu-Isa E, Baiocchi G. Outcomes and toxicity after salvage radiotherapy for vaginal relapse of endometrial cancer. Int J Gynecol Cancer, 2020. e-Pub 2020. PMID: 32376738.
      62. Ning MS, Palmer MB, Shah AK, Chambers LC, Garlock LB, Melson BB, Frank SJ. Three-Year Results of a Prospective Statewide Insurance Coverage Pilot for Proton Therapy: Stakeholder Collaboration Improves Patient Access to Care. JCO Oncol Pract:JOP1900437, 2020. e-Pub 2020. PMID: 32302271.
      63. Mesko S, Ning MS, Lakomy D, Verma V, Chang JY, O'Reilly M, Jeter MD, Gandhi SJ, Lin SH, Nguyen QN, Liao Z, Welsh J, Chen AB, Hahn S, Gomez DR. Thoracic radiation oncology clinical trial accrual and reasons for non-enrollment: results of a large, prospective, multi-year analysis. Int J Radiat Oncol Biol Phys, 2020. e-Pub 2020. PMID: 32360653.
      64. Boyce-Fappiano D, Ning MS, Thaker NG, Pezzi TA, Gjyshi O, Mesko S, Anakwenze C, Olivieri ND, Guzman AB, Incalcaterra JR, Tang C, McAleer MF, Herman J, Ghia AJ. Time-Driven, Activity-Based Cost Analysis of Radiation Treatment Options for Spinal Metastases. JCO Oncol Pract 16(3):e271-e279, 2020. e-Pub 2020. PMID: 31765268.
      65. Mesko S, Wang H, Tung S, Wang C, Pasalic D, Ning MS, Pezzi TA, Moreno AC, Reddy JP, Garden AS, Rosenthal DI, Gunn GB, Frank SJ, Fuller CD, Morrison W, Su SY, Hanna E, Phan J. SABR for Skull Base Malignancies: A Systematic Analysis of Set-Up and Positioning Accuracy. Pract Radiat Oncol, 2020. e-Pub 2020. PMID: 32240823.
      66. Kang J, Ning MS, Feng H, Li H, Bahig H, Brooks ED, Welsh JW, Ye R, Miao H, Chang JY. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms. Int J Radiat Oncol Biol Phys 106(1):90-99, 2020. e-Pub 2020. PMID: 31586665.
      67. McGovern SL, Wages C, Dimmitt A, Sanders C, Martin D, Ning MS, Manning R, Amin M, Zhu XR, Frank SJ, Gunn GB. Proton Therapy in a Pandemic: An Operational Response to the COVID-19 Crisis. Int J Part Ther 7(1):54-57, 2020. e-Pub 2020. PMID: 33094136.
      68. Ning MS, Deegan BJ, Ho JC, Chapman BV, Bishop AJ, Allen PK, Tannir NM, Amini B, Briere TM, Wang XA, Tatsui CE, Rhines LD, Brown PD, Li J, Ghia AJ. Low incidence of late failure and toxicity after spine stereotactic radiosurgery: Secondary analysis of phase I/II trials with long-term follow-up. Radiother Oncol 138:80-85, 2019. e-Pub 2019. PMID: 31252298.
      69. Chapman BV, Swanick CW, Ning MS, Allen PK, Soliman PT, Westin SN, Pardeshi V, Broaddus RR, Lu KH, Jhingran A, Eifel PJ, Klopp AH. Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer. Gynecol Oncol 154(1):22-28, 2019. e-Pub 2019. PMID: 31109659.
      70. Ning MS, Klopp AH, Jhingran A, Lin LL, Eifel PJ, Vedam S, Lawyer AA, Olivieri ND, Guzman AB, Incalcaterra JR, Mesko SM, Pezzi TA, Boyce-Fappiano DR, Shaitelman SF, Frank SJ, Thaker NG. Quantifying institutional resource utilization of adjuvant brachytherapy and intensity-modulated radiation therapy for endometrial cancer via time-driven activity-based costing. Brachytherapy 18(4):445-452, 2019. e-Pub 2019. PMID: 30992185.
      71. Ning MS, Pinnix CC, Chapman BV, Gunther JR, Milgrom SA, Khoury JD, Jain P, Chen WY, Oriabure ON, Badillo MR, Wang LM, Dabaja BS. Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma. Blood Adv 3(13):2035-2039, 2019. e-Pub 2019. PMID: 31289030.
      72. Ning MS, Gomez DR, Shah AK, Kim CR, Palmer MB, Thaker NG, Grosshans DR, Liao Z, Chapman BV, Brooks ED, Tang C, Rosenthal DI, Garden AS, Frank SJ, Gunn GB. The Insurance Approval Process for Proton Radiation Therapy: A Significant Barrier to Patient Care. Int J Radiat Oncol Biol Phys 104(4):724-733, 2019. e-Pub 2019. PMID: 30557675.
      73. Ning MS, Dean MK, Taylor KA, Arzu I, Fleming ND, Mutyala N, Suresh P, Lewis MA, Tu J, Hassid VJ, Joe T, Byler C, Bloom ES, Shah S. Evaluation and Improvement of Bottlenecking in a Multidisciplinary Oncology Clinic: An Electronic Medical Record Intervention. Cureus 11(5):e4583, 2019. e-Pub 2019. PMID: 31309008.
      74. Sapienza LG, Ning MS, Jhingran A, Lin LL, Leão CR, da Silva BB, Pellizzon ACA, Gomes MJL, Baiocchi G. Short-course palliative radiation therapy leads to excellent bleeding control: A single centre retrospective study. Clin Transl Radiat Oncol 14:40-46, 2019. e-Pub 2019. PMID: 30555940.
      75. Kim CR, Kim B, Ning MS, Reddy JP, Liao Z, Tang C, Welsh JW, Mott FE, Shih YT, Gomez DR. Cost Analysis of PET/CT Versus CT as Surveillance for Stage III Non-Small-Cell Lung Cancer After Definitive Radiation Therapy. Clin Lung Cancer 19(4):e517-e528, 2018. e-Pub 2018. PMID: 29685701.
      76. Ning MS, Ahobila V, Jhingran A, Stecklein SR, Frumovitz M, Schmeler KM, Eifel PJ, Klopp AH. Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer. Gynecol Oncol 148(1):132-138, 2018. e-Pub 2018. PMID: 29089122.
      77. Ning MS, Tang L, Gomez DR, Xu T, Luo Y, Huo J, Mouhayar E, Liao Z. Incidence and Predictors of Pericardial Effusion After Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 99(1):70-79, 2017. e-Pub 2017. PMID: 28816165.
      78. Ning MS, Kaminski JM, Pucar D, Shinohara ET. Radiation emergencies: radiation-related brain and lung injury. Journal of Radiation Oncology, 2016. e-Pub 2016.
      79. Ning MS, Perkins SM, Borinstein SC, Holt GE, Stavas MJ, Shinohara ET. Role of radiation in the treatment of non-metastatic osseous Ewing sarcoma. J Med Imaging Radiat Oncol 60(1):119-28, 2016. e-Pub 2016. PMID: 26439449.
      80. Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg S, Beal K, Yu JB, Kavanagh BD, Chiang VL, Camidge DR, Contessa JN. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis. J Clin Oncol 34(2):123-9, 2016. e-Pub 2016. PMID: 26438117.
      81. Stavas MJ, Arneson KO, Ning MS, Attia AA, Phillips SE, Perkins SM, Shinohara ET. The Refusal of Palliative Radiation in Metastatic Non-Small Cell Lung Cancer and Its Prognostic Implications. J Pain Symptom Manage 49(6):1081-1087.e4, 2015. e-Pub 2015. PMID: 25596010.
      82. Ning MS, Perkins SM, Dewees T, Shinohara ET. Evidence of high mortality in long term survivors of childhood medulloblastoma. J Neurooncol 122(2):321-7, 2015. e-Pub 2015. PMID: 25557108.
      83. Ning MS, Kim AS, Prasad N, Levy SE, Zhang H, Andl T. Characterization of the Merkel Cell Carcinoma miRNome. J Skin Cancer 2014:289548, 2014. e-Pub 2014. PMID: 24627810.
      84. Stavas MJ, Shinohara ET, Attia A, Ning MS, Friedman JM, Cmelak AJ. Short course high dose radiotherapy in the treatment of anaplastic thyroid carcinoma. J Thyroid Res 2014:764281, 2014. e-Pub 2014. PMID: 25379320.
      85. Ning MS, Dahir KM, Castellanos EH, McGirt LY. Sodium thiosulfate in the treatment of non-uremic calciphylaxis. J Dermatol 40(8):649-52, 2013. e-Pub 2013. PMID: 23663061.
      86. Ning MS, Price SE, Ta JA, Davies KM. Nucleophilic reactivity of thiolate, hydroxide and phenolate ions towards a model O-arylated diazeniumdiolate prodrug in aqueous and cationic surfactant media. J Phys Org Chem 23(3):220-226, 2010. e-Pub 2010. PMID: 21533014.

      Review Articles

      1. Sezen D, Verma V, He K, Abana CO, Barsoumian H, Ning MS, Tang C, Hurmuz P, Puebla-Osorio N, Chen D, Tendler I, Comeaux N, Nguyen QN, Chang JY, Welsh JW. Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease. Semin Radiat Oncol 31(3):217-226, 2021. e-Pub 2021. PMID: 34090648.
      2. Patel RR, Verma V, Barsoumian H, Ning MS, Chun SG, Tang C, Chang JY, Lee PP, Gandhi S, Balter P, Dunn JD, Chen D, Puebla-Osorio N, Cortez AM, Welsh JW. Use of Multi-Site Radiation Therapy as Systemic Therapy: A New Treatment Approach Personalized by Patient Immune Status. Int J Radiat Oncol Biol Phys 109(2):352-364, 2020. e-Pub 2020. PMID: 32798606.
      3. Ng SSW, Ning MS, Lee P, McMahon RA, Siva S, Chuong MD. Single-Fraction Stereotactic Body Radiation Therapy: A Paradigm During the Coronavirus Disease 2019 (COVID-19) Pandemic and Beyond?. Adv Radiat Oncol 5(4):761-773, 2020. e-Pub 2020. PMID: 32775790.
      4. Lin LL, Lakomy DS, Ning MS, Simpkins F, Jhingran A. Combining novel agents with radiotherapy for gynecologic malignancies: beyond the era of cisplatin. Int J Gynecol Cancer 30(4):409-423, 2020. e-Pub 2020. PMID: 32193219.
      5. Sapienza LG, Salcedo MP, Ning MS, Jhingran A, Klopp AH, Calsavara VF, Schmeler KM, Leite Gomes MJ, de Freitas Carvalho E, Baiocchi G. Pelvic Insufficiency Fractures After External Beam Radiation Therapy for Gynecologic Cancers: A Meta-analysis and Meta-regression of 3929 Patients. Int J Radiat Oncol Biol Phys 106(3):475-484, 2020. e-Pub 2020. PMID: 31580930.
      6. Smith GL, Lopez-Olivo MA, Advani PG, Ning MS, Geng Y, Giordano SH, Volk RJ. Financial Burdens of Cancer Treatment: A Systematic Review of Risk Factors and Outcomes. J Natl Compr Canc Netw 17(10):1184-1192, 2019. e-Pub 2019. PMID: 31590147.
      7. Brooks ED, Ning MS, Verma V, Zhu XR, Chang JY. Proton therapy for non-small cell lung cancer: the road ahead. Transl Lung Cancer Res 8(Suppl 2):S202-S212, 2019. e-Pub 2019. PMID: 31673525.
      8. Sapienza LG, Ning MS, Pellizzon ACA, Jhingran A, Klopp AH, Lin LL, Kollmeier MA, Calsavara VF, Gutierrez NDS, Chojniak R, Gomes MJL, Baiocchi G. Detection of air gaps around the cylinder by postinsertion computed tomography in vaginal cuff brachytherapy: A prospective series, systematic review, and meta-analysis. Brachytherapy 18(5):620-626, 2019. e-Pub 2019. PMID: 31160198.
      9. Sapienza LG, Ning MS, Taguchi S, Calsavara VF, Pellizzon ACA, Gomes MJL, Kowalski LP, Baiocchi G. Altered-fractionation radiotherapy improves local control in early-stage glottic carcinoma: A systematic review and meta-analysis of 1762 patients. Oral Oncol 93:8-14, 2019. e-Pub 2019. PMID: 31109700.
      10. Ning MS, Gomez DR, Heymach JV, Swisher SG. Stereotactic ablative body radiation for oligometastatic and oligoprogressive disease. Transl Lung Cancer Res 8(1):97-106, 2019. e-Pub 2019. PMID: 30788239.
      11. Ning MS, Andl T. Concise review: custodians of the transcriptome: how microRNAs guard stemness in squamous epithelia. Stem Cells 33(4):1047-54, 2015. e-Pub 2015. PMID: 25524325.
      12. Ning MS, Andl T. Control by a hair's breadth: the role of microRNAs in the skin. Cell Mol Life Sci 70(7):1149-69, 2013. e-Pub 2013. PMID: 22983383.

      Book Chapters

      1. He, K, Selek, U, Barsoumian, H, Sezen, D, Ning, M, Puebla-Osorio, N, Schoenhals, JE, Chen, D, Leuschner, C, Cortez, MA, Welsh, J. Mechanisms of Action of Radiotherapy and Immunotherapy in Lung Cancer: Implications for Clinical Practice. In: Advances in Radiation Oncology in Lung Cancer. Springer, 399-414, 2023.
      2. Ning, M, Verma, V, Lin, SH. Thoracic Malignancies: Proton Beam and Carbon‐ion Therapy for Thoracic Cancers and Recurrent Disease. In: Principles and Practice of Particle Therapy. Wiley, 261-285, 2022.
      3. Yoder AK, Ning MS, Joyner MM, Lin LL. Cancer Radiotherapy: General Considerations and Human Radiobiology. In: Locoregional Radionuclide Cancer Therapy: Clinical and Scientific Aspects. Springer, 2021.
      Read More
      Less

      Patient Reviews


      CV information above last modified September 02, 2026

      Request an Appointment

      Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
      Learn more

      Related Links

      • Care Centers and Clinics

      • Departments and Divisions

      • Labs

      Clinical Trials

      Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.
      Learn more

      Help #EndCancer

      Give Now

      Your gift will help make a tremendous difference.
      Donate

      Donate Blood

      Our patients depend on blood and platelet donations.

      Make an appointment

      Shop UT MD Anderson

      Show your support for our mission through branded merchandise.

      View products
      Subscribe to our Cancerwise newsletter
      UT MD Anderson logoUT MD Anderson logo
      • Explore
      • Patients & Family
      • Prevention & Screening
      • Donors & Volunteers
      • For Physicians
      • Research
      • Education & Training
      • Clinical Trials
      • Languages
      • About
      • About UT MD Anderson
      • Careers
      • Blog
      • Newsroom
      • Editorial Standards
      • For Employees
      • Merchandise
      • Title IX Reporting (Sexual Misconduct)
      • Price Transparency
      • Finding Your Way
      • Our Doctors
      • Locations
      • Directions
      • Sitemap
      • DIGITAL ACCESSIBILITY
      • Accessibility Policy MD Anderson works with Level Access to ensure our website is accessible and functional for all users. Free assistive technology is provided for people with physical disabilities. To learn more or to download the assistive technology tool, visit https://www.levelaccess.com/MDAnderson
      • GET IN TOUCH
      • Call
        1-877-632-6789
      • Ask a question
      • Stay Connected
      • Cancerwise Podcast
      • More
      • Website Privacy Policy
      • Legal Statement & Policies
      • Reports to the State
      • Emergency Alert Information
      • State of Texas Links
      • Our Cancer Network
      • Vendors & Suppliers
      UT MD Anderson logo
      The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public.

      © 2026 The University of Texas MD Anderson Cancer Center. All rights reserved.

      Top